Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,68.74,219,DB01076,Atorvastatin
,31545497,inhibitor constant (Ki),"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,26.47,220,DB01076,Atorvastatin
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,16.24,221,DB01076,Atorvastatin
,31545497,Ki,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,10.84,222,DB01076,Atorvastatin
,23885041,flow rate,"The chromatographic separation was achieved within 3.0 min by an isocratic mobile phase consisting of 0.2% formic acid in water-acetonitrile (30:70, v/v), flowing through Agilent Eclipse-plus C18, 100 × 4.6 mm, 3.5 µm analytical column, at a flow rate of 0.6 mL min(-1).",LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23885041/),[ml] / [min],0.6,1941,DB01076,Atorvastatin
,21632965,oral clearance,"The predicted oral clearance values of the drugs investigated ranged from 8.79 to 6320 l/h for tacrolimus and simvastatin, respectively, and were overall within 3-fold of the observed data with the exception of indinavir, atorvastatin, and buspirone.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[l] / [h],8.79 to 6320,1970,DB01076,Atorvastatin
,21632965,CLu(int),"The individual HJM CLu(int) values ranged from 17 to 14,000 μl · min(-1) · mg(-1) for atorvastatin and saquinavir, respectively, and corresponding interindividual variability in CLu(int) estimates ranged from 41 to 67%.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[μl] / [mg·min],"17 to 14,000",1971,DB01076,Atorvastatin
,21632965,F(G),"These in vitro data resulted in predicted F(G) values ranging from 0.03 to 0.94 for simvastatin and indinavir, respectively.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),,0,1972,DB01076,Atorvastatin
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB01076,Atorvastatin
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB01076,Atorvastatin
,32546962,area under the concentration-time curve,"The corresponding values of area under the concentration-time curve from zero to the last measurable time point were 1.02 (0.97-1.08) and 1.02 (0.98-1.07), respectively.",Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32546962/),,1.02,3935,DB01076,Atorvastatin
,32546962,area under the concentration-time curve,"The corresponding values of area under the concentration-time curve from zero to the last measurable time point were 1.02 (0.97-1.08) and 1.02 (0.98-1.07), respectively.",Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32546962/),,1.02,3936,DB01076,Atorvastatin
,33246047,Cmax,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[ng] / [ml],940,4442,DB01076,Atorvastatin
,33246047,AUC0-12,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[h·ng] / [ml],8759,4443,DB01076,Atorvastatin
,33246047,Cmax,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[ng] / [ml],635,4444,DB01076,Atorvastatin
,33246047,AUC0-12,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[h·ng] / [ml],4367,4445,DB01076,Atorvastatin
,33246047,Cmax,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[ng] / [ml],515,4446,DB01076,Atorvastatin
,33246047,AUC0-12,The in vivo oral absorption testing confirmed the bioavailability of the prepared At-NPs to be as follows: (Cmax = 940 ng/ml and AUC0-12 = 8759 ng.h/ml) > Lipitor® (Cmax = 635 ng/ml and AUC0-12 = 4367 ng.h/ml) > At (Cmax = 515 ng/ml and AUC0-12 = 2517 ng.h/ml).,Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246047/),[h·ng] / [ml],2517,4447,DB01076,Atorvastatin
,28617150,zeta potential,The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between -34 ± 0.29 and -23 ± 0.36 mV.,Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28617150/),mv,-,4801,DB01076,Atorvastatin
,28617150,zeta potential,The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between -34 ± 0.29 and -23 ± 0.36 mV.,Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28617150/),mv,34,4802,DB01076,Atorvastatin
,28617150,zeta potential,The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between -34 ± 0.29 and -23 ± 0.36 mV.,Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28617150/),mv,23,4803,DB01076,Atorvastatin
>,28617150,encap,They also showed high encapsulation efficiency (>87%) and amorphous state of the drug in lipid matrix.,Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28617150/),%,87,4804,DB01076,Atorvastatin
,23264940,flow rate,"The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),[ml] / [min],0.8,5160,DB01076,Atorvastatin
,23264940,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),min,3.0,5161,DB01076,Atorvastatin
,23767355,run time,A run time of 4 min made it possible to determine many plasma samples/day.,Development and validation of a liquid chromatography/ mass spectrometry method for the simultaneous quantitation of rosuvastatin and ezetimibe in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23767355/),min,4,8468,DB01076,Atorvastatin
,26839733,flow rate,Chromatographic separation was performed on an BDS Hypersil C18 column (250 × 4.6 mm; 5 μm) via gradient elution with mobile phase consisting of 10 mM phosphoric acid (sodium) buffer solution (pH = 2.6 adjusted with 85% orthophosphoric acid) : acetonitrile : methanol with flow rate of 1 mL·min(-1).,"Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839733/),[ml] / [min],1,8719,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,559.2,9038,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,440.2,9039,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,575.3,9040,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,440.4,9041,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,575.0,9042,DB01076,Atorvastatin
,21309001,m/z,"The m/z of ATO, o-HATO and p-HATO are 559.2/440.2, 575.3/440.4 and 575.0/440.4 respectively.",Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21309001/),,440.4,9043,DB01076,Atorvastatin
,12548150,flow rate,The mobile phase consisted of an aqueous solution containing 20 mmol/L dibasic sodium dihydrogen phosphate with 1 mmol/L sodium lauryl sulfate adjusted to pH 7 with phosphoric acid and acetonitrile (70:30 v/v) delivered at a flow rate of 1.0 mL/min.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),[ml] / [min],1.0,10307,DB01076,Atorvastatin
,12548150,retention times,"Under these conditions, the retention times for FV and IS were 8.8 and 10.6 minutes, respectively.",Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),min,8.8,10308,DB01076,Atorvastatin
,12548150,retention times,"Under these conditions, the retention times for FV and IS were 8.8 and 10.6 minutes, respectively.",Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),min,10.6,10309,DB01076,Atorvastatin
,12548150,recovery,The recovery ranged from 88% to 96%.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),%,88,10310,DB01076,Atorvastatin
,12548150,recovery,The recovery ranged from 88% to 96%.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),%,96,10311,DB01076,Atorvastatin
>,34330719,hepatic extraction ratio,"After the first dose, all statins were rapidly cleared from the circulation (hepatic extraction ratio > 0.7) and excreted into the bile.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,0.7,26059,DB01076,Atorvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,7.2,26060,DB01076,Atorvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,3.1,26061,DB01076,Atorvastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,2.6,26062,DB01076,Atorvastatin
,12942850,elimination half-life,"It is mainly eliminated in the faeces, with an elimination half-life in humans of between 13 and 21 hours.","[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942850/),h,13 and 21,26698,DB01076,Atorvastatin
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],13.78,27508,DB01076,Atorvastatin
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],11.46,27509,DB01076,Atorvastatin
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],33.08,27510,DB01076,Atorvastatin
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],21.67,27511,DB01076,Atorvastatin
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.81,27512,DB01076,Atorvastatin
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.18,27513,DB01076,Atorvastatin
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],3.42,27514,DB01076,Atorvastatin
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],2.08,27515,DB01076,Atorvastatin
,19034423,Cmax,"Critically ill patients with sepsis had a significantly higher Cmax and AUC as compared to healthy volunteers [110.5(86.5) vs. 5.9(2.50) ng/ml, p < 0.01 and 1,051(810) vs. 67(48) ng h/ml (p < 0.0001)], respectively.",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[ng] / [ml],110.5,30706,DB01076,Atorvastatin
,19034423,AUC,"Critically ill patients with sepsis had a significantly higher Cmax and AUC as compared to healthy volunteers [110.5(86.5) vs. 5.9(2.50) ng/ml, p < 0.01 and 1,051(810) vs. 67(48) ng h/ml (p < 0.0001)], respectively.",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[ng] / [ml],5.9,30707,DB01076,Atorvastatin
,19034423,AUC,"Critically ill patients with sepsis had a significantly higher Cmax and AUC as compared to healthy volunteers [110.5(86.5) vs. 5.9(2.50) ng/ml, p < 0.01 and 1,051(810) vs. 67(48) ng h/ml (p < 0.0001)], respectively.",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[h·ng] / [ml],"1,051",30708,DB01076,Atorvastatin
,19034423,AUC,"Critically ill patients with sepsis had a significantly higher Cmax and AUC as compared to healthy volunteers [110.5(86.5) vs. 5.9(2.50) ng/ml, p < 0.01 and 1,051(810) vs. 67(48) ng h/ml (p < 0.0001)], respectively.",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[h·ng] / [ml],67,30709,DB01076,Atorvastatin
,19034423,AUC,"The AUC was significantly higher for those patients on concomitant CYP 450 inhibitor therapy as compared to those patients not on inhibitors (1,518 +/- 793 vs. 584 +/- 540 ng h/ml, p = 0.0260).",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[h·ng] / [ml],"1,518",30710,DB01076,Atorvastatin
,19034423,AUC,"The AUC was significantly higher for those patients on concomitant CYP 450 inhibitor therapy as compared to those patients not on inhibitors (1,518 +/- 793 vs. 584 +/- 540 ng h/ml, p = 0.0260).",A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034423/),[h·ng] / [ml],584,30711,DB01076,Atorvastatin
,21253970,recovery,The accuracy of the method was proved as the mean recovery was 96.4 ± 4.3%.,Generation of a specific polyclonal antibody with high affinity to atorvastatin and its employment in the development of ELISA for determination of atorvastatin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21253970/),%,96.4,32308,DB01076,Atorvastatin
,25609600,flow rate,The system was operated at 25°C using a mobile phase consisting of acetonitrile and phosphate buffer (pH 3.0) in the gradient ratio at a flow rate of 1 mL min(-1) with ultraviolet detection monitored at 232 nm.,"Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609600/),[ml] / [min],1,32433,DB01076,Atorvastatin
,24490758,apparent bioavailability,"In vivo results showed an overall enhancement in the apparent bioavailability (83% and 434% more than Lipitor® and plain amorphous ATO tablets, respectively).",Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490758/),%,83,33235,DB01076,Atorvastatin
,24490758,apparent bioavailability,"In vivo results showed an overall enhancement in the apparent bioavailability (83% and 434% more than Lipitor® and plain amorphous ATO tablets, respectively).",Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490758/),%,434,33236,DB01076,Atorvastatin
,23381936,CL/F,"Based on the final model, the typical CL/F estimates for a Tanner Stage 1 patient (35 kg weight) and Tanner Stage ≥2 (50 kg weight), would be 553 and 543 L/hour, respectively.",Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381936/),[l] / [h],553,37683,DB01076,Atorvastatin
,23381936,CL/F,"Based on the final model, the typical CL/F estimates for a Tanner Stage 1 patient (35 kg weight) and Tanner Stage ≥2 (50 kg weight), would be 553 and 543 L/hour, respectively.",Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381936/),[l] / [h],543,37684,DB01076,Atorvastatin
,28435225,Cmax,"Minor homozygotes (76.5 ng/mL) of SLCO1B1 c.-910G>A showed higher Cmax than heterozygotes (34.0 ng/mL) and major homozygotes (33.5 ng/mL, false discovery rate P=0.040).",Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],34.0,43531,DB01076,Atorvastatin
,28435225,Cmax,"Minor homozygotes (76.5 ng/mL) of SLCO1B1 c.-910G>A showed higher Cmax than heterozygotes (34.0 ng/mL) and major homozygotes (33.5 ng/mL, false discovery rate P=0.040).",Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],33.5,43532,DB01076,Atorvastatin
,28435225,Cmax,Cmax and the area under the plasma concentration curve from hour 0 to infinity (AUC∞) were higher in carriers of the SLCO1B1*17 haplotype that included c.-910G>A than in noncarriers (46.1 vs 32.8 ng/mL for Cmax; 221.5 vs 154.2 ng/mL for AUC∞).,Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],46.1,43533,DB01076,Atorvastatin
,28435225,Cmax,Cmax and the area under the plasma concentration curve from hour 0 to infinity (AUC∞) were higher in carriers of the SLCO1B1*17 haplotype that included c.-910G>A than in noncarriers (46.1 vs 32.8 ng/mL for Cmax; 221.5 vs 154.2 ng/mL for AUC∞).,Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],32.8,43534,DB01076,Atorvastatin
,28435225,AUC∞,Cmax and the area under the plasma concentration curve from hour 0 to infinity (AUC∞) were higher in carriers of the SLCO1B1*17 haplotype that included c.-910G>A than in noncarriers (46.1 vs 32.8 ng/mL for Cmax; 221.5 vs 154.2 ng/mL for AUC∞).,Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],221.5,43535,DB01076,Atorvastatin
,28435225,AUC∞,Cmax and the area under the plasma concentration curve from hour 0 to infinity (AUC∞) were higher in carriers of the SLCO1B1*17 haplotype that included c.-910G>A than in noncarriers (46.1 vs 32.8 ng/mL for Cmax; 221.5 vs 154.2 ng/mL for AUC∞).,Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],154.2,43536,DB01076,Atorvastatin
,28435225,Cmax,"SLCO1B3 c.334G>T homozygotes (63.0 ng/mL) also showed higher Cmax than heterozygotes (34.7 ng/mL) and major homozygotes (31.4 ng/mL, FDR P=0.037).",Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],34.7,43537,DB01076,Atorvastatin
,28435225,Cmax,"SLCO1B3 c.334G>T homozygotes (63.0 ng/mL) also showed higher Cmax than heterozygotes (34.7 ng/mL) and major homozygotes (31.4 ng/mL, FDR P=0.037).",Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435225/),[ng] / [ml],31.4,43538,DB01076,Atorvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB01076,Atorvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB01076,Atorvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB01076,Atorvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB01076,Atorvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB01076,Atorvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB01076,Atorvastatin
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],2.1,54148,DB01076,Atorvastatin
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],72,54149,DB01076,Atorvastatin
,22396916,maximum drug dissolution rate,"The best formulation, AT4, consisting of Ethyl cellulose, DSS and Poly Ox®, had a maximum drug dissolution rate of 97.86 %, as compared to Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate of only 54% during a period of 12 h in acidic media.",Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules using Minimum Additives. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396916/),%,97.86,55846,DB01076,Atorvastatin
,22396916,rate,"The best formulation, AT4, consisting of Ethyl cellulose, DSS and Poly Ox®, had a maximum drug dissolution rate of 97.86 %, as compared to Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate of only 54% during a period of 12 h in acidic media.",Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules using Minimum Additives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396916/),,54,55847,DB01076,Atorvastatin
,26855565,maximum plasma concentration,"The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet.","Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26855565/),[ng] / [ml],54,56237,DB01076,Atorvastatin
,26855565,maximum plasma concentration,"The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet.","Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26855565/),[ng] / [ml],34,56238,DB01076,Atorvastatin
,26855565,time to reach the maximum plasma concentration,"The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet.","Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26855565/),h,12,56239,DB01076,Atorvastatin
,26855565,time to reach the maximum plasma concentration,"The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet.","Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26855565/),h,72,56240,DB01076,Atorvastatin
more,15935741,extraction efficiency,The extraction efficiency for the carboxylic acid metabolite of clopidogrel was more than 85.76%.,Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935741/),%,85.76,56303,DB01076,Atorvastatin
,27393428,λ(max,"The plasma samples were assayed using an isocratic High Performance Liquid Chromatography (HPLC) system of Agilent technologies USA consisted of an isocratic pump with column of Thermo Electron Corporation USA (ODS hypersil C(18) 4.6 mm x 250 mm), a UV-visible detector set at λ(max) 237 nm.",Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),,237,56884,DB01076,Atorvastatin
,27393428,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of atorvastatin (Mean ± SEM) for the reference product (A) found to be 13.739±0.210ng/ml & 13.374±0.145ng/ml for test product (B).,Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),[ng] / [ml],13.739,56885,DB01076,Atorvastatin
,27393428,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of atorvastatin (Mean ± SEM) for the reference product (A) found to be 13.739±0.210ng/ml & 13.374±0.145ng/ml for test product (B).,Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),[ng] / [ml],13.374,56886,DB01076,Atorvastatin
,27393428,T(max),"T(max) values (Mean±SEM) of atorvastatin were 1.222 ±0.060 hours and 1.167±0.057 hours for reference and test products, respectively.",Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),h,1.222,56887,DB01076,Atorvastatin
,27393428,T(max),"T(max) values (Mean±SEM) of atorvastatin were 1.222 ±0.060 hours and 1.167±0.057 hours for reference and test products, respectively.",Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),h,1.167,56888,DB01076,Atorvastatin
,27393428,AUC(0-oo),The values of AUC(0-oo) (Mean ± SEM) for the reference (A) and test product (B) were 73.955 ± 1.715ng.h/ml and 77.773 ± 1.858ng.,Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),[h·ng] / [ml],73.955,56889,DB01076,Atorvastatin
,27393428,AUC(0-oo),The values of AUC(0-oo) (Mean ± SEM) for the reference (A) and test product (B) were 73.955 ± 1.715ng.h/ml and 77.773 ± 1.858ng.,Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393428/),ng,77.773,56890,DB01076,Atorvastatin
,8988072,elimination half-life,Mean elimination half-life values ranged from 11 to 24 hours.,"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988072/),h,11 to 24,58785,DB01076,Atorvastatin
,26997703,flow rate,"The bioanalytical method was developed in rat plasma by using Thermo beta-basic C18 (100×4.6 mm, 5 μm) and mobile phase was composed of dibasic phosphate buffer (pH 3.0):acetonitrile in the ratio of 55:45 at a flow rate of 1 ml/min with ultraviolet detection monitored at 240 nm.",Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26997703/),[ml] / [min],1,59711,DB01076,Atorvastatin
more,26997703,recovery,The mean recovery (%) was more than 92.8% for both the drugs using protein precipitation method.,Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26997703/),%,92.8,59712,DB01076,Atorvastatin
,28481663,zeta potential,"Optimised ATC-SNEDDS resulted in droplets size of 5.66 nm, zeta potential of -19.52 mV, t90 of 5.43 min and completely released ATC within 30 min irrespective of pH of the medium.",Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481663/),mv,19.52,59944,DB01076,Atorvastatin
,28481663,t90,"Optimised ATC-SNEDDS resulted in droplets size of 5.66 nm, zeta potential of -19.52 mV, t90 of 5.43 min and completely released ATC within 30 min irrespective of pH of the medium.",Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481663/),min,5.43,59945,DB01076,Atorvastatin
,9848883,time to achieve this peak,"Peak TRL (d<1.006 g/mL; Sf>20) triglyceride concentrations were decreased 29% by atorvastatin, and the time to achieve this peak was delayed (5.2 versus 2.3 hours; P<0.01).",The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848883/),h,5.2,60170,DB01076,Atorvastatin
,9848883,time to achieve this peak,"Peak TRL (d<1.006 g/mL; Sf>20) triglyceride concentrations were decreased 29% by atorvastatin, and the time to achieve this peak was delayed (5.2 versus 2.3 hours; P<0.01).",The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848883/),h,2.3,60171,DB01076,Atorvastatin
,9848883,fractional clearance rate,"Analysis of the RP kinetic parameters revealed that the TRL fractional clearance rate was increased significantly, 1.4-fold (3.093 versus 2.276 pools/h; P=0.012), with atorvastatin treatment.",The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848883/),[pools] / [h],3.093,60172,DB01076,Atorvastatin
,9848883,fractional clearance rate,"Analysis of the RP kinetic parameters revealed that the TRL fractional clearance rate was increased significantly, 1.4-fold (3.093 versus 2.276 pools/h; P=0.012), with atorvastatin treatment.",The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848883/),[pools] / [h],2.276,60173,DB01076,Atorvastatin
,30130726,flow rate,"Separation of AC and rosuvastatin calcium (internal standard, IS) were achieved on a Dikma Leapsil C18 reversed phase column (100 × 2.1 mm, 2.7 μm) with gradient elution using 0.2% (v/v) formic acid in water and acetonitrile as mobile phases, at the flow rate of 0.3 mL/min.",UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30130726/),[ml] / [min],0.3,60920,DB01076,Atorvastatin
,34031791,% DE30,The formulation F8 showed high dissolution performance (% DE30 value of 80.65 ± 3.05) among the other formulations.,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),,80.65,61857,DB01076,Atorvastatin
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],2864.33,61858,DB01076,Atorvastatin
,34031791,AUC0-t,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],5594.95,61859,DB01076,Atorvastatin
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],317.82,61860,DB01076,Atorvastatin
,34031791,AUC0-t,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],573.94,61861,DB01076,Atorvastatin
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],852.72,61862,DB01076,Atorvastatin
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],4837.4,61863,DB01076,Atorvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,54.2,65539,DB01076,Atorvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,50.1,65540,DB01076,Atorvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,65.2,65541,DB01076,Atorvastatin
,16470513,absolute recoveries,"The average absolute recoveries of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin and the IS from spiked plasma samples were 54.2 +/- 3.2, 50.1 +/- 3.8, 65.2 +/- 3.6 and 71.7 +/- 2.7%, respectively.",Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),%,71.7,65542,DB01076,Atorvastatin
,16470513,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470513/),min,2.5,65543,DB01076,Atorvastatin
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,-,68303,DB01076,Atorvastatin
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,21.7,68304,DB01076,Atorvastatin
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,22.7,68305,DB01076,Atorvastatin
,29452493,loading capacity,The loading capacity varied from 17.9 ± 1.21 to 34.1 ± 1.16%.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),%,17.9,68306,DB01076,Atorvastatin
,29452493,loading capacity,The loading capacity varied from 17.9 ± 1.21 to 34.1 ± 1.16%.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),%,34.1,68307,DB01076,Atorvastatin
,16149712,flow rate,"The chromatographic conditions were as follows: analytical 125 x 4 mm (i.d.) Nucleosil C8 column (5 microm particle size), mobile phase consisting of sodium dihydrogen phosphate buffer-acetonitrile (60:40, v/v) adjusted to pH 5.5 at a flow rate of 1.5 ml/min, UV detection at 245 nm.",A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149712/),[ml] / [min],1.5,68949,DB01076,Atorvastatin
,16149712,detection limit,The detection limit for atorvastatin in plasma was 1 ng ml(-1).,A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149712/),[ng] / [ml],1,68950,DB01076,Atorvastatin
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.8,69158,DB01076,Atorvastatin
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.3,69159,DB01076,Atorvastatin
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.20,69160,DB01076,Atorvastatin
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.22,69161,DB01076,Atorvastatin
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.38,69162,DB01076,Atorvastatin
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.39,69163,DB01076,Atorvastatin
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.05,69164,DB01076,Atorvastatin
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.04,69165,DB01076,Atorvastatin
,29403791,flow rate,The reconstituted samples were chromatographed on a Alltima HP C18 column by using a 60:40 (v/v) mixture of acetonitrile and 10 mM ammonium acetate (pH 3.0) as the mobile phase at a flow rate of 1.1 mL/min.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),[ml] / [min],1.1,74796,DB01076,Atorvastatin
,29403791,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),min,2.5,74797,DB01076,Atorvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB01076,Atorvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB01076,Atorvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB01076,Atorvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB01076,Atorvastatin
,20629042,flow rate,"The reconstituted samples were chromatographed on C(18) column by pumping 0.1% formic acid-acetonitrile (15:85, v/v) at a flow rate of 1 mL/min.","Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),[ml] / [min],1,77437,DB01076,Atorvastatin
,20629042,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,"Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),min,2.5,77438,DB01076,Atorvastatin
,19374892,IC50,Rifampicin is a potent inhibitor of SLCO1B1 (IC50 1.5 umol/l) and SLCO1B1 521T>C functional genetic polymorphism alters the kinetics of atorvastatin in vivo.,Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19374892/),[umol] / [l],1.5,81142,DB01076,Atorvastatin
,21950641,area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-∞)),"When subjects had not received clarithromycin pretreatment, the area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-∞)) of atorvastatin lactone was 36% higher in nonexpressors than in expressors (median 47.6 ng•hr/ml [interquartile range (IQR) 37.8-64.3 ng•hr/ml] vs 34.9 ng•hr/ml [IQR 21.6-42.2 ng•hr/ml], p=0.038).",Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950641/),[h·ng] / [ml],47.6,82272,DB01076,Atorvastatin
,21950641,area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-∞)),"When subjects had not received clarithromycin pretreatment, the area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-∞)) of atorvastatin lactone was 36% higher in nonexpressors than in expressors (median 47.6 ng•hr/ml [interquartile range (IQR) 37.8-64.3 ng•hr/ml] vs 34.9 ng•hr/ml [IQR 21.6-42.2 ng•hr/ml], p=0.038).",Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950641/),[h·ng] / [ml],34.9,82273,DB01076,Atorvastatin
,15522524,mass transitions,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,460.4,84213,DB01076,Atorvastatin
,15522524,mass transitions,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,356.3,84214,DB01076,Atorvastatin
,15522524,mass transitions,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,559.2,84215,DB01076,Atorvastatin
,15522524,m/z,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,460.4,84216,DB01076,Atorvastatin
,15522524,m/z,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,356.3,84217,DB01076,Atorvastatin
,15522524,m/z,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,559.2,84218,DB01076,Atorvastatin
,15522524,m/z,"The mass transitions m/z 460.4 --> 356.3 and 559.2 --> 440.3 were used to measure I and II, respectively.","Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),,440.3,84219,DB01076,Atorvastatin
,15522524,Sample analysis time,Sample analysis time of 2min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,"Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522524/),min,2,84220,DB01076,Atorvastatin
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB01076,Atorvastatin
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB01076,Atorvastatin
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB01076,Atorvastatin
,31556335,peak plasma concentration,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[ng] / [ml],18.28,87978,DB01076,Atorvastatin
,31556335,peak plasma concentration,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[ng] / [ml],24.13,87979,DB01076,Atorvastatin
,31556335,oral clearance,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[l] / [h·kg],4.57,87980,DB01076,Atorvastatin
,31556335,oral clearance,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[l] / [h·kg],1.79,87981,DB01076,Atorvastatin
,31556335,intrinsic clearance rate,"In the rat liver microsome systems, the intrinsic clearance rate of ALDP was decreased by the pretreatment with atorvastatin (39.26 ± 2.1 vs. 33.24 ± 3.3 μL/min/mg protein).",Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[μl] / [mg·min],39.26,87982,DB01076,Atorvastatin
,31556335,intrinsic clearance rate,"In the rat liver microsome systems, the intrinsic clearance rate of ALDP was decreased by the pretreatment with atorvastatin (39.26 ± 2.1 vs. 33.24 ± 3.3 μL/min/mg protein).",Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[μl] / [mg·min],33.24,87983,DB01076,Atorvastatin
,20975528,AUC(dn),"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[h·ng] / [mg·ml],2.35,89148,DB01076,Atorvastatin
,20975528,AUC(dn),"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[h·ng] / [mg·ml],2.06,89149,DB01076,Atorvastatin
,20975528,Cmax(dn),"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),,0.39,89150,DB01076,Atorvastatin
,20975528,Cmax(dn),"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),,0.40,89151,DB01076,Atorvastatin
,20975528,AUC(dn,"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[h·mg·ng] / [kg·ml],157.5,89152,DB01076,Atorvastatin
,20975528,AUC(dn,"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[h·mg·ng] / [kg·ml],156.4,89153,DB01076,Atorvastatin
,20975528,Cmax(,"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[mg·ng] / [kg·ml],26.2,89154,DB01076,Atorvastatin
,20975528,Cmax(,"AUC(dn) (Asian = 2.35, Caucasian = 2.06 [ng·hr·mL(-1)]/mg) and Cmax(dn) (Asian = 0.39, Caucasian = 0.40 Cmax(dn,wt)) and the equivalent dose-per-bodyweight normalized values for atorvastatin (AUC(dn,wt): Asian = 157.5, Caucasian = 156.4 [ng·hr·mL(-1)]/[mg·kg(-1)]; Cmax(dn,wt): Asian = 26.2, Caucasian = 30.3 [ng·mL(-1)]/[mg·kg(-1)]) were similar in both ethnic groups.",Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975528/),[mg·ng] / [kg·ml],30.3,89155,DB01076,Atorvastatin
,26016780,particle size,"The mean particle size, polydispersity index (PDI) and % drug entrapment efficiency of optimized NLC were 203.56 ± 8.57 nm, 0.27 ± 0.028 and 83.66 ± 5.69, respectively.","Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26016780/),nm,203.56,90132,DB01076,Atorvastatin
,26016780,polydispersity index (PDI),"The mean particle size, polydispersity index (PDI) and % drug entrapment efficiency of optimized NLC were 203.56 ± 8.57 nm, 0.27 ± 0.028 and 83.66 ± 5.69, respectively.","Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26016780/),,0.27,90133,DB01076,Atorvastatin
,26016780,% drug entrapment efficiency,"The mean particle size, polydispersity index (PDI) and % drug entrapment efficiency of optimized NLC were 203.56 ± 8.57 nm, 0.27 ± 0.028 and 83.66 ± 5.69, respectively.","Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26016780/),,83.66,90134,DB01076,Atorvastatin
,15497662,Cmax,"The mean Cmax were 16.37 ng/mL and 17.05 ng/mL, while the mean AUC0-t were 103.61 ng x h/mL and 102.55 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[ng] / [ml],16.37,90156,DB01076,Atorvastatin
,15497662,Cmax,"The mean Cmax were 16.37 ng/mL and 17.05 ng/mL, while the mean AUC0-t were 103.61 ng x h/mL and 102.55 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[ng] / [ml],17.05,90157,DB01076,Atorvastatin
,15497662,AUC0-t,"The mean Cmax were 16.37 ng/mL and 17.05 ng/mL, while the mean AUC0-t were 103.61 ng x h/mL and 102.55 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[h·ng] / [ml],103.61,90158,DB01076,Atorvastatin
,15497662,AUC0-t,"The mean Cmax were 16.37 ng/mL and 17.05 ng/mL, while the mean AUC0-t were 103.61 ng x h/mL and 102.55 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[h·ng] / [ml],102.55,90159,DB01076,Atorvastatin
,15497662,AUC0-inf,"The mean AUC0-inf were 118.10 ng x h/mL and 117.13 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[h·ng] / [ml],118.10,90160,DB01076,Atorvastatin
,15497662,AUC0-inf,"The mean AUC0-inf were 118.10 ng x h/mL and 117.13 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of atorvastatin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),[h·ng] / [ml],117.13,90161,DB01076,Atorvastatin
,15497662,tmax,The median tmax was 0.67 h for both the test tablet and the reference product.,Bioequivalence study of atorvastatin tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),h,0.67,90162,DB01076,Atorvastatin
,15497662,t(1/2 el),The mean t(1/2 el) was 11.85 h for the test formulation and 13.28 h for the reference formulation.,Bioequivalence study of atorvastatin tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),h,11.85,90163,DB01076,Atorvastatin
,15497662,t(1/2 el),The mean t(1/2 el) was 11.85 h for the test formulation and 13.28 h for the reference formulation.,Bioequivalence study of atorvastatin tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497662/),h,13.28,90164,DB01076,Atorvastatin
,8568017,time of maximum observed concentration (tmax),"Mean time of maximum observed concentration (tmax) and elimination half-life (t1/2) values were 5.9 and 32.0 hours, respectively, with food and 2.6 and 35.7 hours, respectively, without food.","Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568017/),h,5.9,90311,DB01076,Atorvastatin
,8568017,time of maximum observed concentration (tmax),"Mean time of maximum observed concentration (tmax) and elimination half-life (t1/2) values were 5.9 and 32.0 hours, respectively, with food and 2.6 and 35.7 hours, respectively, without food.","Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568017/),h,2.6,90312,DB01076,Atorvastatin
,8568017,elimination half-life (t1/2),"Mean time of maximum observed concentration (tmax) and elimination half-life (t1/2) values were 5.9 and 32.0 hours, respectively, with food and 2.6 and 35.7 hours, respectively, without food.","Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568017/),h,32.0,90313,DB01076,Atorvastatin
,8568017,elimination half-life (t1/2),"Mean time of maximum observed concentration (tmax) and elimination half-life (t1/2) values were 5.9 and 32.0 hours, respectively, with food and 2.6 and 35.7 hours, respectively, without food.","Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568017/),h,2.6,90314,DB01076,Atorvastatin
,8568017,elimination half-life (t1/2),"Mean time of maximum observed concentration (tmax) and elimination half-life (t1/2) values were 5.9 and 32.0 hours, respectively, with food and 2.6 and 35.7 hours, respectively, without food.","Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568017/),h,35.7,90315,DB01076,Atorvastatin
,31695118,absolute bioavailability,"Atorvastatin, a favored option for hyperlipidemia exhibits the problem of poor gastric solubility and low absolute bioavailability (12%) along with higher pre-systemic clearance (>80%).","Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31695118/),%,12,92166,DB01076,Atorvastatin
,16671968,absorption rate,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),1/[h],1,95456,DB01076,Atorvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,14,95457,DB01076,Atorvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2,95458,DB01076,Atorvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2.5,95459,DB01076,Atorvastatin
,16671968,input rate (K(in)),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),[g] / [d·l],0.14,95460,DB01076,Atorvastatin
,16671968,inhibition fraction of K(in),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),,0.21,95461,DB01076,Atorvastatin
,16671968,dose,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95462,DB01076,Atorvastatin
,16671968,L,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95463,DB01076,Atorvastatin
,21324753,flow rate,"The method showed adequate separation for rosuvastatin and atorvastatin and best resolution was achieved with Brownlee analytical C18 column (150×4.6 mm, 5 μm) using methanol-water (68:32, v/v; pH adjusted to 3.0 with trifluoroacetic acid) as a mobile phase at a flow rate of 1.5 ml/min and wavelength of 241 nm.","Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21324753/),[ml] / [min],1.5,95580,DB01076,Atorvastatin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6)·cells],599,95659,DB01076,Atorvastatin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6)·cells],375,95660,DB01076,Atorvastatin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6],413,95661,DB01076,Atorvastatin
,18426955,passive permeability,The high passive permeability of indomethacin (237 +/- 63 microl/min/10(6) cells) clearly negated the effect of the active transport on the overall disposition.,"Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[μl] / [10·min],237,95662,DB01076,Atorvastatin
,9549635,la,"Although the elimination rate constant, lambda z (0.579), was significantly correlated with creatinine clearance, neither maximum plasma concentration (Cmax, -0.361) nor oral clearance (Cl/F, 0.306) were; thus, steady-state exposure is not altered.",Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549635/),,0.579,98354,DB01076,Atorvastatin
,21833652,AUC,"Study 1: AUC, troponin T: atorvastatin 29.6 ± 34.8 μg/L versus control 25.0 ± 22.0 μg/L:P > 0.05.",Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21833652/),[μg] / [l],29.6,101820,DB01076,Atorvastatin
,21833652,AUC,"Study 1: AUC, troponin T: atorvastatin 29.6 ± 34.8 μg/L versus control 25.0 ± 22.0 μg/L:P > 0.05.",Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21833652/),[μg] / [l],25.0,101821,DB01076,Atorvastatin
,21833652,AUC,"Study 2: AUC, troponin T: atorvastatin 21.8 ± 14.3 μg/L versus control 20.9 ± 8.7 μg/L:P > 0.05.",Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21833652/),[μg] / [l],21.8,101822,DB01076,Atorvastatin
,21833652,AUC,"Study 2: AUC, troponin T: atorvastatin 21.8 ± 14.3 μg/L versus control 20.9 ± 8.7 μg/L:P > 0.05.",Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21833652/),[μg] / [l],20.9,101823,DB01076,Atorvastatin
,32371153,rate constants,"Thus, rate constants ranging between 0.69 and 8.3 h-1 were applied in the PK simulations.",A physiologically-based drug absorption modeling for orally disintegrating tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371153/),1/[h],0.69 and 8.3,102747,DB01076,Atorvastatin
,31786357,Cmax,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[ng] / [ml],1146,102893,DB01076,Atorvastatin
,31786357,AUC0-12,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[h·ng] / [ml],"9,993.4",102894,DB01076,Atorvastatin
,31786357,Cmax,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[ng] / [ml],642.3,102895,DB01076,Atorvastatin
,31786357,AUC0-12,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[h·ng] / [ml],4427.4,102896,DB01076,Atorvastatin
,31786357,Cmax,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[ng] / [ml],517.6,102897,DB01076,Atorvastatin
,31786357,AUC0- 12,"In vivo absorption of the tested formula (Cmax = 1146 ng/ml and AUC0-12 to 9,993.4 ng.h/ml) was greater than Lipitor® (Cmax = 642.3 ng/ml and AUC0-12 = 4427.4 ng.h/ml) and AT (Cmax = 517.6 ng/ml and AUC0- 12 = 2,473.7 ng.h/ml).","Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786357/),[h·ng] / [ml],"2,473.7",102898,DB01076,Atorvastatin
,26094911,droplet size,The droplet size of the disintegrated SMET oil globules was within 2.73 to 4.77 μm.,Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26094911/),μm,2.73 to 4.77,105842,DB01076,Atorvastatin
,29232954,oral bioavailability,The results revealed that the oral bioavailability of two selected AC-NPs formulations was 235% and 169% relative to Lipitor.,Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29232954/),%,235,106497,DB01076,Atorvastatin
,29232954,oral bioavailability,The results revealed that the oral bioavailability of two selected AC-NPs formulations was 235% and 169% relative to Lipitor.,Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29232954/),%,169,106498,DB01076,Atorvastatin
,22801271,C(max),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],10.6,108007,DB01076,Atorvastatin
,22801271,C(max),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],10.6,108008,DB01076,Atorvastatin
,22801271,t(1/2z),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.4,108009,DB01076,Atorvastatin
,22801271,t(1/2z),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.4,108010,DB01076,Atorvastatin
,22801271,AUC(0-t),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],54.2,108011,DB01076,Atorvastatin
,22801271,AUC(0-t),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],51.7,108012,DB01076,Atorvastatin
,22801271,C(max),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],7.8,108013,DB01076,Atorvastatin
,22801271,C(max),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],7.6,108014,DB01076,Atorvastatin
,22801271,t(1/2z),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,12.3,108015,DB01076,Atorvastatin
,22801271,t(1/2z),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.9,108016,DB01076,Atorvastatin
,22801271,AUC(0-t),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],96.8,108017,DB01076,Atorvastatin
,22801271,AUC(0-t),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],92.3,108018,DB01076,Atorvastatin
,22801271,C(max),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],0.5,108019,DB01076,Atorvastatin
,22801271,C(max),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],0.4,108020,DB01076,Atorvastatin
,22801271,t(1/2z),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,18.4,108021,DB01076,Atorvastatin
,22801271,t(1/2z),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,23.3,108022,DB01076,Atorvastatin
,22801271,AUC(0-t),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],15.9,108023,DB01076,Atorvastatin
,22801271,AUC(0-t),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],13.8,108024,DB01076,Atorvastatin
,22801271,relative bioavailability,"The relative bioavailability of AT and o-OAT in test formulation were (105.3 ± 20.7)% and (107.8 ± 23.2)%, respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),%,105.3,108025,DB01076,Atorvastatin
,22801271,relative bioavailability,"The relative bioavailability of AT and o-OAT in test formulation were (105.3 ± 20.7)% and (107.8 ± 23.2)%, respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),%,107.8,108026,DB01076,Atorvastatin
,29498757,flow rate,"Ammonium formate and acetonitrile, pumped isocraticaly at a flow rate of 0.25 mL/min, were used as a mobile phase.",Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498757/),[ml] / [min],0.25,108282,DB01076,Atorvastatin
<,29498757,run time,"A short run time, of <1.5 min, permits analysis of a large number of plasma samples per batch.",Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498757/),min,1.5,108283,DB01076,Atorvastatin
,26428157,Cmax,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [ml],134.29,109323,DB01076,Atorvastatin
,26428157,Cmax,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [ml],42.36,109324,DB01076,Atorvastatin
,26428157,AUC0-∞,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [h·ml],2103.47,109325,DB01076,Atorvastatin
,26428157,AUC0-∞,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [h·ml],580.43,109326,DB01076,Atorvastatin
,26428157,Tmax,The complex exhibited 3.2-fold increase in Cmax with 5.4-fold decrease in Tmax (0.5 ± 0.2 vs. 2.7 ± 0.8h) in comparison to pure ERL.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),h,0.5,109327,DB01076,Atorvastatin
,26428157,Tmax,The complex exhibited 3.2-fold increase in Cmax with 5.4-fold decrease in Tmax (0.5 ± 0.2 vs. 2.7 ± 0.8h) in comparison to pure ERL.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),h,2.7,109328,DB01076,Atorvastatin
,22771234,flow rate,"After one-step liquid-liquid extraction (LLE) using methyl tert-butyl ether (MTBE), celecoxib and atorvastatin (internal standard, IS) were eluted on a Luna HILIC column with an isocratic mobile phase, consisting of 10mM ammonium formate buffer (adjusted to pH 3.0 with formic acid):methanol (5:95, v/v) at a flow rate of 0.2 mL/min.",Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),[ml] / [min],0.2,115777,DB01076,Atorvastatin
>,22771234,S/N,The achieved lower limit of quantitation (LLOQ) was 10 ng/mL (S/N>10) and the standard calibration curve for celecoxib was linear (correlation coefficients were >0.9995) over the studied concentration range (10-2000 ng/mL).,Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),,10,115778,DB01076,Atorvastatin
<,22771234,run time,The chromatographic run time for each plasma sample was <2 min.,Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),min,2,115779,DB01076,Atorvastatin
,22393830,disintegration time,"Apart from improved stability compared to pure AT, disintegration time of 27s, hardness of 5 kg and favorable mouth feel were achieved.","Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22393830/),s,27,117215,DB01076,Atorvastatin
,33434916,Lower Limit of Detection (LLOD),Method was found to be linear (2-100 ng/mL) with Lower Limit of Detection (LLOD) 2 ng/mL.,Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33434916/),[ng] / [ml],2,121896,DB01076,Atorvastatin
,23631744,IC50,"4. Inhibition of organic anion transporting polypeptide 1B1 by CP-778875 (IC50 = 2.14 ± 0.40 μM) could be the dominant cause of the pharmacokinetic interaction as CP-778875 did not exhibit significant inhibition of cytochrome P450 3A4/3A5, multidrug resistant protein 1 or breast cancer resistant protein, which are also involved in the hepatobiliary disposition of atorvastatin.","Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631744/),μM,2.14,123512,DB01076,Atorvastatin
,25960179,lag time,"The final formula of floating spheroids was optimized on the basis of shape (spherical), diameter (0.47 mm), lag time (20 s), and floating time (> 32 h).",Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25960179/),s,20,127630,DB01076,Atorvastatin
,9551707,Cmax (the maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·ng] / [ml],5.11,128283,DB01076,Atorvastatin
,9551707,Cmax (the maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·ng] / [ml],4.54,128284,DB01076,Atorvastatin
,9551707,tmax (the time to reach maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,2.2,128285,DB01076,Atorvastatin
,9551707,tmax (the time to reach maximum concentration),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,1.3,128286,DB01076,Atorvastatin
,9551707,AUC0-24 (area under the concentration-time curve from time 0 h to 24 h),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·h·ng] / [ml],58.6,128287,DB01076,Atorvastatin
,9551707,AUC0-24 (area under the concentration-time curve from time 0 h to 24 h),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),[eq·h·ng] / [ml],58.5,128288,DB01076,Atorvastatin
,9551707,t1/2 (terminal half-life),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,10.1,128289,DB01076,Atorvastatin
,9551707,t1/2 (terminal half-life),"Mean values for Cmax (the maximum concentration) were 5.11 ng eq.ml(-1) and 4.54 ng eq.ml(-1), for tmax (the time to reach maximum concentration) 2.2 h and 1.3 h, for AUC0-24 (area under the concentration-time curve from time 0 h to 24 h) 58.6 ng eq.h.ml(-1) and 58.5 ng eq.h.ml(-1), and for t1/2 (terminal half-life) 10.1 h and 17.0 h, respectively, following administration of atorvastatin alone and atorvastatin with cimetidine.",Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551707/),h,17.0,128290,DB01076,Atorvastatin
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,91.39,135206,DB01076,Atorvastatin
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,99.28,135207,DB01076,Atorvastatin
,18193692,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),min,3.5,135208,DB01076,Atorvastatin
,18193692,flow rate,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),[ml] / [min],0.50,135209,DB01076,Atorvastatin
,27125455,Carr's index,"The resultant powders were free flowing with an angle of repose <40° and Carr's index 5-20%, regardless of the solid carrier types.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),,5-20,135442,DB01076,Atorvastatin
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,345,135443,DB01076,Atorvastatin
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,216,135444,DB01076,Atorvastatin
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,160,135445,DB01076,Atorvastatin
,27125455,RBAs,"Additionally, at a reduced dose of ATV equivalent to 5mg/kg, the RBAs of S(M)-SMEDDS and S(S)-SMEDDS compared to that of SMEDDS were 101% and 65%, respectively.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,101,135446,DB01076,Atorvastatin
,27125455,RBAs,"Additionally, at a reduced dose of ATV equivalent to 5mg/kg, the RBAs of S(M)-SMEDDS and S(S)-SMEDDS compared to that of SMEDDS were 101% and 65%, respectively.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,65,135447,DB01076,Atorvastatin
,31068304,recovery,"The intra-day and inter-day precisions were all less than 13%, and the recovery was between 66.50% and 82.67%; the stability of the plasma samples met the requirements of testing.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),%,66.50,135817,DB01076,Atorvastatin
,31068304,recovery,"The intra-day and inter-day precisions were all less than 13%, and the recovery was between 66.50% and 82.67%; the stability of the plasma samples met the requirements of testing.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),%,82.67,135818,DB01076,Atorvastatin
,31068304,AUC0-24 h,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[h·μg] / [l],438.78,135819,DB01076,Atorvastatin
,31068304,AUC0-24 h,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[h·μg] / [l],927.43,135820,DB01076,Atorvastatin
,31068304,CLz/F,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[l] / [h·kg],23.89,135821,DB01076,Atorvastatin
,31068304,CLz/F,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[l] / [h·kg],10.43,135822,DB01076,Atorvastatin
,31068304,Cmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[μg] / [l],149.62,135823,DB01076,Atorvastatin
,31068304,Cmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[μg] / [l],159.37,135824,DB01076,Atorvastatin
,31068304,t1/2,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,5.08,135825,DB01076,Atorvastatin
,31068304,t1/2,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,5.58,135826,DB01076,Atorvastatin
,31068304,Tmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,0.37,135827,DB01076,Atorvastatin
,31068304,Tmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,3.60,135828,DB01076,Atorvastatin
,14742751,AUC,Atorvastatin coadministration increased the cyclosporine AUC by 9% (range 0-20.6%; 3018 vs 3290 ng.h/mL; p = 0.04).,Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742751/),[h·ng] / [ml],3018,138469,DB01076,Atorvastatin
,14742751,AUC,Atorvastatin coadministration increased the cyclosporine AUC by 9% (range 0-20.6%; 3018 vs 3290 ng.h/mL; p = 0.04).,Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742751/),[h·ng] / [ml],3290,138470,DB01076,Atorvastatin
,21182938,clearance,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[l] / [h],27.83,139576,DB01076,Atorvastatin
,21182938,peak plasma concentration,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[μg] / [ml],18.39,139577,DB01076,Atorvastatin
,21182938,area under the plasma concentration time curve,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[μg] / [h·ml],120.02,139578,DB01076,Atorvastatin
,21182938,elimination half-life,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),h,4.09,139579,DB01076,Atorvastatin
,10631627,K(m),"In this model system, atorvastatin exhibited efflux or secretion kinetics with a K(m) of 110 microM.",Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631627/),μM,110,141142,DB01076,Atorvastatin
,31852330,swelling index,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,140.48,142329,DB01076,Atorvastatin
,31852330,floating duration,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,8.53,142330,DB01076,Atorvastatin
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],36.84,146673,DB01076,Atorvastatin
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],48.68,146674,DB01076,Atorvastatin
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],135.82,146675,DB01076,Atorvastatin
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],77.28,146676,DB01076,Atorvastatin
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,2.62,146677,DB01076,Atorvastatin
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,3.32,146678,DB01076,Atorvastatin
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,48.2,146679,DB01076,Atorvastatin
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,36.7,146680,DB01076,Atorvastatin
,20818835,first-order absorption rate constant,The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3.5 h-1 fixed); oral clearance (504 L/h [29%]); apparent volume of the central compartment (3250 L [16.5%]); and apparent volume of the peripheral compartment (2170 L [9.3%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),1/[h],3.5,158933,DB01076,Atorvastatin
,20818835,oral clearance,The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3.5 h-1 fixed); oral clearance (504 L/h [29%]); apparent volume of the central compartment (3250 L [16.5%]); and apparent volume of the peripheral compartment (2170 L [9.3%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),[l] / [h],504,158934,DB01076,Atorvastatin
,20818835,apparent volume of the central compartment,The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3.5 h-1 fixed); oral clearance (504 L/h [29%]); apparent volume of the central compartment (3250 L [16.5%]); and apparent volume of the peripheral compartment (2170 L [9.3%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),l,3250,158935,DB01076,Atorvastatin
,20818835,apparent volume of the peripheral compartment,The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3.5 h-1 fixed); oral clearance (504 L/h [29%]); apparent volume of the central compartment (3250 L [16.5%]); and apparent volume of the peripheral compartment (2170 L [9.3%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),l,2170,158936,DB01076,Atorvastatin
,20818835,apparent clearance,The main pharmacokinetic parameters of atorvastatin lactone (mean [RSE]) were the apparent clearance to atorvastatin acid (24 L/h [154%]); apparent total body clearance (116 L/h [9.5%]); and apparent volume of distribution (137 L [33.7%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),[l] / [h],24,158937,DB01076,Atorvastatin
,20818835,apparent total body clearance,The main pharmacokinetic parameters of atorvastatin lactone (mean [RSE]) were the apparent clearance to atorvastatin acid (24 L/h [154%]); apparent total body clearance (116 L/h [9.5%]); and apparent volume of distribution (137 L [33.7%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),[l] / [h],116,158938,DB01076,Atorvastatin
,20818835,apparent volume of distribution,The main pharmacokinetic parameters of atorvastatin lactone (mean [RSE]) were the apparent clearance to atorvastatin acid (24 L/h [154%]); apparent total body clearance (116 L/h [9.5%]); and apparent volume of distribution (137 L [33.7%]).,Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818835/),l,137,158939,DB01076,Atorvastatin
,29412674,particle size,The mean particle size and zeta potential of submicron emulsion were 122.7 nm and -22.7 mV.,Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412674/),nm,122.7,159324,DB01076,Atorvastatin
,29412674,zeta potential,The mean particle size and zeta potential of submicron emulsion were 122.7 nm and -22.7 mV.,Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412674/),m,22.7,159325,DB01076,Atorvastatin
,29412674,area under the curve (AUC),"After oral administration, the atorvastatin plasma concentration of the emulsion group was much higher than that of free drug and the area under the curve (AUC) reached to 4.033 mg/L·h (2.58-fold).",Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412674/),[mg] / [h·l],4.033,159326,DB01076,Atorvastatin
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],155.9,160864,DB01076,Atorvastatin
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],151.3,160865,DB01076,Atorvastatin
,32104340,en,"And the drug loading and encapsulation efficiency were about 8% and 71%, respectively.",The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104340/),%,8,162085,DB01076,Atorvastatin
,32104340,en,"And the drug loading and encapsulation efficiency were about 8% and 71%, respectively.",The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104340/),%,71,162086,DB01076,Atorvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],72.00,162798,DB01076,Atorvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],65.57,162799,DB01076,Atorvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],15.33,162800,DB01076,Atorvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],8.15,162801,DB01076,Atorvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],75.79,162802,DB01076,Atorvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],32.88,162803,DB01076,Atorvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],17.07,162804,DB01076,Atorvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],7.01,162805,DB01076,Atorvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],48.0,169350,DB01076,Atorvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],14.1,169351,DB01076,Atorvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],3.10,169352,DB01076,Atorvastatin
,22124880,IC₅₀,"The uptake of [¹⁴C]aliskiren and [³H]fexofenadine was linear in OATP1A2-expressing cells and was reduced by naringin, with IC₅₀ values of 75.5 ± 11.6 and 24.2 ± 2.0 μM, respectively.",Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22124880/),μM,75.5,175449,DB01076,Atorvastatin
,22124880,IC₅₀,"The uptake of [¹⁴C]aliskiren and [³H]fexofenadine was linear in OATP1A2-expressing cells and was reduced by naringin, with IC₅₀ values of 75.5 ± 11.6 and 24.2 ± 2.0 μM, respectively.",Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22124880/),μM,24.2,175450,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,16.0,183649,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,43.5,183650,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,15.2,183651,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,28.4,183652,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,5.2,183653,DB01076,Atorvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,6.3,183654,DB01076,Atorvastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01076,Atorvastatin
,23369879,constant flow rate,"Adequate chromatographic separation was achieved using Phenomenex Synergi 4u polar-RP 80A (150mm×4.6mm, 4μm) column in the isocratic elution mode and the eluent was water/methanol (14:86%, v/v) adjusted by trichloroacetic acid to pH 3.2 which was delivered isocratically at constant flow rate of 0.50mL/min.",Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23369879/),[ml] / [min],0.50,189319,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],151,190014,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],75,190015,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],17,190016,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],548,190017,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],167,190018,DB01076,Atorvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],289,190019,DB01076,Atorvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],24 319,190020,DB01076,Atorvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],26 760,190021,DB01076,Atorvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],15 565,190022,DB01076,Atorvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],14 571,190023,DB01076,Atorvastatin
,29322864,Cmax,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[ng] / [ml],23.87,192886,DB01076,Atorvastatin
,29322864,Cmax,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[ng] / [ml],38.94,192887,DB01076,Atorvastatin
,29322864,AUC(0-t),"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[h·ng] / [ml],41.01,192888,DB01076,Atorvastatin
,29322864,AUC(0-t),"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[h·ng] / [ml],77.28,192889,DB01076,Atorvastatin
,29322864,t1/2,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),h,1.91,192890,DB01076,Atorvastatin
,29322864,t1/2,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),h,2.74,192891,DB01076,Atorvastatin
,29322864,metabolic stability (t1/2),The metabolic stability (t1/2) of AC was also decreased (25.7 ± 5.2 vs. 42.5 ± 6.1) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),,25.7,192892,DB01076,Atorvastatin
,29322864,metabolic stability (t1/2),The metabolic stability (t1/2) of AC was also decreased (25.7 ± 5.2 vs. 42.5 ± 6.1) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),,42.5,192893,DB01076,Atorvastatin
,26150693,globule size,"Optimized SNEDDS formula exhibited mean globule size of 73.5 nm, zeta potential magnitude of -24.1 mV, and 13.5 μs/cm of electrical conductivity.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),nm,73.5,195618,DB01076,Atorvastatin
,26150693,zeta potential,"Optimized SNEDDS formula exhibited mean globule size of 73.5 nm, zeta potential magnitude of -24.1 mV, and 13.5 μs/cm of electrical conductivity.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),mv,-,195619,DB01076,Atorvastatin
,26150693,zeta potential,"Optimized SNEDDS formula exhibited mean globule size of 73.5 nm, zeta potential magnitude of -24.1 mV, and 13.5 μs/cm of electrical conductivity.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),mv,24.1,195620,DB01076,Atorvastatin
,26150693,electrical conductivity,"Optimized SNEDDS formula exhibited mean globule size of 73.5 nm, zeta potential magnitude of -24.1 mV, and 13.5 μs/cm of electrical conductivity.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),[μs] / [cm],13.5,195621,DB01076,Atorvastatin
,26150693,Bioavailability,"Bioavailability estimation in Wistar albino rats revealed an augmentation in ATR bioavailability, relative to ATR suspension and the commercial tablets, from optimized ATR SNEDDS and NS formulations by 193.81% and 155.31%, respectively.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),%,193.81,195622,DB01076,Atorvastatin
,26150693,Bioavailability,"Bioavailability estimation in Wistar albino rats revealed an augmentation in ATR bioavailability, relative to ATR suspension and the commercial tablets, from optimized ATR SNEDDS and NS formulations by 193.81% and 155.31%, respectively.",Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150693/),%,155.31,195623,DB01076,Atorvastatin
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB01076,Atorvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB01076,Atorvastatin
,11772327,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772327/),h,20,197177,DB01076,Atorvastatin
,32393664,total plasma concentration,"Assuming the highest antiviral target exposure (total plasma concentration of 4.1 mg/l), all studies had about one-tenth the necessary concentration for in vitro viral inhibition.",Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393664/),[mg] / [l],4.1,198539,DB01076,Atorvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB01076,Atorvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB01076,Atorvastatin
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB01076,Atorvastatin
,28466393,entrapment efficiency,"Extensive optimization of nanoformulation resulted into the formation of AT-MG NPs with particle size 247.7 ± 10.9 nm, PDI 0.219 ± 0.07, and entrapment efficiency 58.7 ± 5.3%.",Improved Stability and Enhanced Oral Bioavailability of Atorvastatin Loaded Stearic Acid Modified Gelatin Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28466393/),%,58.7,200531,DB01076,Atorvastatin
,31450089,flow,"ATV and its five metabolites were separated on a C18 column using as mobile phase a mixture of 0.2% formic acid and acetonitrile (55:45, v/v) at a flow of 0.4 mL/min.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),[ml] / [min],0.4,200595,DB01076,Atorvastatin
,31450089,unbound fraction,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),%,9.38,200596,DB01076,Atorvastatin
,31450089,maximum plasma concentration,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),[ng] / [ml],9.52,200597,DB01076,Atorvastatin
,31450089,time to reach maximum plasma concentration,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),h,0.98,200598,DB01076,Atorvastatin
,31450089,apparent total clearance,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),[l] / [h],742.90,200599,DB01076,Atorvastatin
,31450089,apparent distribution volume,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),l,9005,200600,DB01076,Atorvastatin
,31450089,AUC metabolite/ATV ratios,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),,0.06,200601,DB01076,Atorvastatin
,31450089,AUC metabolite/ATV ratios,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),,0.94,200602,DB01076,Atorvastatin
,31450089,AUC metabolite/ATV ratios,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),,1.43,200603,DB01076,Atorvastatin
,31450089,AUC metabolite/ATV ratios,"The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n = 15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC.",Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31450089/),,0,200604,DB01076,Atorvastatin
,19721239,total run time of analysis,The total run time of analysis was 6 min with the retention time of lovastatin being 4.3 min.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),min,6,201844,DB01076,Atorvastatin
,19721239,retention time,The total run time of analysis was 6 min with the retention time of lovastatin being 4.3 min.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),min,4.3,201845,DB01076,Atorvastatin
,19721239,limit of detection (LOD),"The limit of detection (LOD) and limit of quantification (LOQ) for lovastatin were 0.5 and 1 ng/ml, respectively.",A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),[ng] / [ml],0.5,201846,DB01076,Atorvastatin
,19721239,limit of quantification (LOQ),"The limit of detection (LOD) and limit of quantification (LOQ) for lovastatin were 0.5 and 1 ng/ml, respectively.",A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),[ng] / [ml],1,201847,DB01076,Atorvastatin
,19721239,relative recovery,The mean relative recovery of lovastatin from human plasma by the developed method was 88.61+/-7.00%.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),%,88.61,201848,DB01076,Atorvastatin
,12911366,area under the curve,Atorvastatin patients demonstrated a greater area under the curve (889.4 (standard deviation 388.6) ng-h.ml-1) vs. control patients (629.1 (standard deviation 197.2) ng-h.ml-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[ng-h] / [ml],889.4,203185,DB01076,Atorvastatin
,12911366,area under the curve,Atorvastatin patients demonstrated a greater area under the curve (889.4 (standard deviation 388.6) ng-h.ml-1) vs. control patients (629.1 (standard deviation 197.2) ng-h.ml-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[ng-h] / [ml],629.1,203186,DB01076,Atorvastatin
,12911366,clearance,Patients taking atorvastatin also demonstrated a decreased clearance (0.18 (standard deviation 0.08) l-kg. h-1) vs. control patients (0.27 (standard deviation 0.08) l-kg.h-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[l-kg] / [h],0.18,203187,DB01076,Atorvastatin
,12911366,clearance,Patients taking atorvastatin also demonstrated a decreased clearance (0.18 (standard deviation 0.08) l-kg. h-1) vs. control patients (0.27 (standard deviation 0.08) l-kg.h-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[l-kg] / [h],0.27,203188,DB01076,Atorvastatin
,21069099,area under the plasma concentration-time curve,"The mean values for the area under the plasma concentration-time curve for atorvastatin and ortho-hydroxy atorvastatin were 63.1 and 46.9 ng.h/mL, respectively.",Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069099/),[h·ng] / [ml],63.1,203685,DB01076,Atorvastatin
,21069099,area under the plasma concentration-time curve,"The mean values for the area under the plasma concentration-time curve for atorvastatin and ortho-hydroxy atorvastatin were 63.1 and 46.9 ng.h/mL, respectively.",Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069099/),[h·ng] / [ml],46.9,203686,DB01076,Atorvastatin
,8877677,Plasma elimination half-life (t1/2),Plasma elimination half-life (t1/2) ranged from 14.7 to 57.6 hours.,"Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877677/),h,14.7 to 57.6,204105,DB01076,Atorvastatin
,20040338,area under the concentration-time curve from time 0 to infinity (AUC0-infinity),"For SLCO1B1 genotypes, the mean area under the concentration-time curve from time 0 to infinity (AUC0-infinity) of atorvastatin was 148.2 ng x hr/ml for *15/*15 subjects (n = 3), which was significantly larger than for 1a/*15 and *1b/*15 (n = 8) (80.7 ng x hr/ml, p = 0.0121) and also larger than for *1a/*1a, *1a/*1b and *1b/*1b (n = 17) (66.3 ng x hr/ml, p = 0.0018).",Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040338/),[h·ng] / [ml],148.2,205584,DB01076,Atorvastatin
,20040338,area under the concentration-time curve from time 0 to infinity (AUC0-infinity),"For SLCO1B1 genotypes, the mean area under the concentration-time curve from time 0 to infinity (AUC0-infinity) of atorvastatin was 148.2 ng x hr/ml for *15/*15 subjects (n = 3), which was significantly larger than for 1a/*15 and *1b/*15 (n = 8) (80.7 ng x hr/ml, p = 0.0121) and also larger than for *1a/*1a, *1a/*1b and *1b/*1b (n = 17) (66.3 ng x hr/ml, p = 0.0018).",Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040338/),[h·ng] / [ml],80.7,205585,DB01076,Atorvastatin
,20040338,area under the concentration-time curve from time 0 to infinity (AUC0-infinity),"For SLCO1B1 genotypes, the mean area under the concentration-time curve from time 0 to infinity (AUC0-infinity) of atorvastatin was 148.2 ng x hr/ml for *15/*15 subjects (n = 3), which was significantly larger than for 1a/*15 and *1b/*15 (n = 8) (80.7 ng x hr/ml, p = 0.0121) and also larger than for *1a/*1a, *1a/*1b and *1b/*1b (n = 17) (66.3 ng x hr/ml, p = 0.0018).",Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040338/),[h·ng] / [ml],66.3,205586,DB01076,Atorvastatin
,20445535,Time to maximum plasma concentration (C(max)),Time to maximum plasma concentration (C(max)) increased from 1.2 h before surgery to 2.3 h after surgery (P = 0.03).,Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20445535/),h,1.2,206104,DB01076,Atorvastatin
,20445535,Time to maximum plasma concentration (C(max)),Time to maximum plasma concentration (C(max)) increased from 1.2 h before surgery to 2.3 h after surgery (P = 0.03).,Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20445535/),h,2.3,206105,DB01076,Atorvastatin
,21864678,bioavailability,The plasma-concentration time profile of AT after oral administration of CH-AT nano-conjugate (2574±95.4 ng/mL) to rat exhibited nearly 5-fold increase in bioavailability compared with AT suspension (583±55.5 ng/mL).,Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864678/),[ng] / [ml],583,207780,DB01076,Atorvastatin
,18501538,particle,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),n,68.7,208984,DB01076,Atorvastatin
,18501538,specific surface area,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[m2] / [g],120.35,208985,DB01076,Atorvastatin
,18501538,specific surface area,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[m2] / [g],79.78,208986,DB01076,Atorvastatin
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],1121.4,208987,DB01076,Atorvastatin
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],3249.5,208988,DB01076,Atorvastatin
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],3016.1,208989,DB01076,Atorvastatin
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],2227.8,208990,DB01076,Atorvastatin
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],2099.9,208991,DB01076,Atorvastatin
,21879394,Oral bioavailability,Oral bioavailability of atorvastatin calcium (ATC) is very low (only 14%) due to instability and incomplete intestinal absorption and/or extensive gut wall extraction.,Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879394/),%,14,211547,DB01076,Atorvastatin
,21879394,lag time,"The best formulation (F4) consisting of hypromellose, sodium bicarbonate, polyethylene oxide, docusate sodium, mannitol, crosscarmellose sodium, and magnesium stearate, gave floating lag time of 56 ± 4.16 s and good matrix integrity with in vitro dissolution of 98.2% in 12 h.",Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879394/),s,56,211548,DB01076,Atorvastatin
,22415894,flow rate,"The chromatographic separation was achieved on a Hypurity Advance (4.6 × 50 mm, 5 µm) column using a mobile phase consisting of 0.1% formic acid buffer-acetonitrile (20:80, v/v) at flow rate of 0.8 mL/min.",Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415894/),[ml] / [min],0.8,212745,DB01076,Atorvastatin
,22415894,total run time of analysis,"The total run time of analysis was 3 min and elution of AT, NA and IS occurred at 1.06, 1.84 and 0.92 min, respectively.",Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415894/),min,3,212746,DB01076,Atorvastatin
,32605304,AUC ratio,The AUC ratio (IISOR+MET group/IIISOR group) for sorafenib was equal to 0.6.,"Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32605304/),,0.6,214737,DB01076,Atorvastatin
,12769127,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12769127/),h,20,214857,DB01076,Atorvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,171.4,221656,DB01076,Atorvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,146.3,221657,DB01076,Atorvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,173.7,221658,DB01076,Atorvastatin
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,157.3,221659,DB01076,Atorvastatin
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB01076,Atorvastatin
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB01076,Atorvastatin
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB01076,Atorvastatin
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB01076,Atorvastatin
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.9,226634,DB01076,Atorvastatin
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.1,226635,DB01076,Atorvastatin
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],77.3,234749,DB01076,Atorvastatin
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],45.9,234750,DB01076,Atorvastatin
,24346850,V max,"Moreover, SMN-treated animals showed a significant (P < 0.05) reduction of V max (59.4 ± 6.1 pM/min/mg).",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],59.4,234751,DB01076,Atorvastatin
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],6.98,234752,DB01076,Atorvastatin
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],4.35,234753,DB01076,Atorvastatin
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.52,234754,DB01076,Atorvastatin
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.33,234755,DB01076,Atorvastatin
excess of,28352156,radial crushing strength,ODTs containing amlodipine (5 mg) and atorvastatin (10 mg) either alone or in combination rapidly disintegrated (<30 s) while displaying a radial crushing strength in excess of 100 N and friability ≤1%.,"Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28352156/),n,100,235923,DB01076,Atorvastatin
≤,28352156,friability,ODTs containing amlodipine (5 mg) and atorvastatin (10 mg) either alone or in combination rapidly disintegrated (<30 s) while displaying a radial crushing strength in excess of 100 N and friability ≤1%.,"Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28352156/),%,1,235924,DB01076,Atorvastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB01076,Atorvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB01076,Atorvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB01076,Atorvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB01076,Atorvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB01076,Atorvastatin
,8921332,Cmax,Plasma drug concentrations during Week 15 increased with dose to a Cmax of 1820 +/- 1020 ng eq/ml at 175 mg/kg.,"Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921332/),[eq·ng] / [ml],1820,239564,DB01076,Atorvastatin
,8921332,Cmax,Plasma drug concentrations on premating treatment Day 14 increased with dose to a Cmax of 7030 +/- 3680 ng eq/ml at 225 mg/ kg.,"Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921332/),[eq·ng] / [ml],7030,239565,DB01076,Atorvastatin
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,8.4-10.6,242817,DB01076,Atorvastatin
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,6.6,242818,DB01076,Atorvastatin
,31141832,flow rate,"Adequate separation for both analytes was achieved with a Waters C18 column (250 × 4.6 mm, 5 μm) using acetonitrile-5 mm sodium acetate buffer (70:30, v/v; pH adjusted to 3.5 with acetic acid) as a mobile phase at a flow rate of 1.0 mL/min and wavelength of 254 nm.","A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141832/),[ml] / [min],1.0,246051,DB01076,Atorvastatin
,31594719,Ki,Atorvastatin showed ATP-dependent transport in BCRP-expressing membrane vesicles and it inhibited rosuvastatin transport with Ki of 6.3 ± 2.9 μM (mean ± SD).,Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31594719/),μM,6.3,246384,DB01076,Atorvastatin
,14531725,oral bioavailability,"However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.",Clinical pharmacokinetics of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,14,249256,DB01076,Atorvastatin
,14531725,volume of distribution,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),l,381,249257,DB01076,Atorvastatin
exceeds,14531725,plasma protein binding,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,98,249258,DB01076,Atorvastatin
,14531725,total plasma clearance,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),[ml] / [min],625,249259,DB01076,Atorvastatin
,14531725,half-life,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),h,7,249260,DB01076,Atorvastatin
,19398603,area,"Furthermore, the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0 to 10 hours showed no significant differences among 3 statins (simvastatin: 0.32 +/- 0.09, atorvastatin: 0.31 +/- 0.09, and pitavastatin: 0.31 +/- 0.12).",Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398603/),,0,249583,DB01076,Atorvastatin
,26150716,oral bioavailability,"This work focuses on the development of atorvastatin utilizing zein, a natural, safe, and biocompatible polymer, as a nanosized formulation in order to overcome the poor oral bioavailability (12%) of the drug.",Optimized zein nanospheres for improved oral bioavailability of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150716/),%,12,250072,DB01076,Atorvastatin
,26150716,encapsulation efficiency,"The optimized atorvastatin-zein formulation had a mean particle size of 183 nm, a loading efficiency of 14.86%, and an encapsulation efficiency of 29.71%.",Optimized zein nanospheres for improved oral bioavailability of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150716/),%,29,250073,DB01076,Atorvastatin
,26150716,cumulative amount,"The in vitro dissolution assay displayed an initial burst effect, with a cumulative amount of atorvastatin released of 41.76% and 82.3% after 12 and 48 hours, respectively.",Optimized zein nanospheres for improved oral bioavailability of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150716/),%,41.76,250074,DB01076,Atorvastatin
,26150716,cumulative amount,"The in vitro dissolution assay displayed an initial burst effect, with a cumulative amount of atorvastatin released of 41.76% and 82.3% after 12 and 48 hours, respectively.",Optimized zein nanospheres for improved oral bioavailability of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150716/),%,82.3,250075,DB01076,Atorvastatin
,20678686,C(max),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],8.78,255520,DB01076,Atorvastatin
,20678686,C(max),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],10.76,255521,DB01076,Atorvastatin
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],10.76,255522,DB01076,Atorvastatin
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],38.22,255523,DB01076,Atorvastatin
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],42.73,255524,DB01076,Atorvastatin
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],47.32,255525,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],42.73,255526,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],44.51,255527,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],5.78,255528,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],5.77,255529,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],47.32,255530,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],48.47,255531,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],52.36,255532,DB01076,Atorvastatin
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],53.14,255533,DB01076,Atorvastatin
,26888941,IC50,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,295,255854,DB01076,Atorvastatin
,26888941,KI,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,216,255855,DB01076,Atorvastatin
,26888941,kinact,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),1/[min],0.0179,255856,DB01076,Atorvastatin
,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,157,255857,DB01076,Atorvastatin
>,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,500,255858,DB01076,Atorvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,1.59,255859,DB01076,Atorvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.47,255860,DB01076,Atorvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.26,255861,DB01076,Atorvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,4.38,255862,DB01076,Atorvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],1.44,256262,DB01076,Atorvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],30.6,256263,DB01076,Atorvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],12.7,256264,DB01076,Atorvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],62.9,256265,DB01076,Atorvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],0.84-1.2,256266,DB01076,Atorvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],14-35,256267,DB01076,Atorvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],11-19,256268,DB01076,Atorvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],123-185,256269,DB01076,Atorvastatin
,16454200,flow rate,The mobile phase consisted of acetonitrile:0.1 mol/L ammonium acetate buffer (pH 4.0) (65:35% v/v) at a flow rate of 1.0 ml/min.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),[ml] / [min],1.0,258959,DB01076,Atorvastatin
,16454200,injection volume,The injection volume was 25 microl.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),μl,25,258960,DB01076,Atorvastatin
,16454200,limit of detection,"The limit of quantification was 25 ng/mL, the limit of detection was 8 ng/ml.",HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),[ng] / [ml],8,258961,DB01076,Atorvastatin
,16454200,total chromatographic analysis time,The total chromatographic analysis time was within 9 min.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),min,9,258962,DB01076,Atorvastatin
,23526241,AUC0-t,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],52.69,265364,DB01076,Atorvastatin
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 378.62,265365,DB01076,Atorvastatin
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[1] / [h],0.75,265366,DB01076,Atorvastatin
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.17,265367,DB01076,Atorvastatin
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.50,265368,DB01076,Atorvastatin
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[ng] / [ml],985.90,265369,DB01076,Atorvastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB01076,Atorvastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB01076,Atorvastatin
,28167473,plasma concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.16069,271090,DB01076,Atorvastatin
,28167473,plasma concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.3227,271091,DB01076,Atorvastatin
,28167473,urine concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),[μg] / [ml],1.5994,271092,DB01076,Atorvastatin
,28167473,urine concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),[μg] / [ml],0.8665,271093,DB01076,Atorvastatin
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),m,1.224,271094,DB01076,Atorvastatin
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),m,1.550,271095,DB01076,Atorvastatin
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.2064,271096,DB01076,Atorvastatin
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.0641,271097,DB01076,Atorvastatin
,22775412,first-order absorption rate constant,Parent drug was absorbed orally with a population estimate first-order absorption rate constant of 0.457 h(-1).,Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),1/[h],0.457,272031,DB01076,Atorvastatin
,22775412,apparent oral clearance (CL/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],231,272032,DB01076,Atorvastatin
,22775412,apparent central compartment volume of distribution after oral administration (V(1)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],315,272033,DB01076,Atorvastatin
,22775412,apparent central compartment volume of distribution after oral administration (V(1)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,325,272034,DB01076,Atorvastatin
,22775412,apparent peripheral compartment volume of distribution after oral administration (V(2)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,4910,272035,DB01076,Atorvastatin
,22775412,apparent total clearance of atorvastatin lactone (CL(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],85.4,272036,DB01076,Atorvastatin
,22775412,apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],166,272037,DB01076,Atorvastatin
,22775412,apparent volume of distribution of,"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],166,272038,DB01076,Atorvastatin
,22775412,V(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,249,272039,DB01076,Atorvastatin
,28344015,systemic availability,"Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability (14%) after oral administration in addition to other side effects on the gastrointestinal tract, liver and muscle.",Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344015/),%,14,272369,DB01076,Atorvastatin
,28344015,entrapment efficiency (EE%),The results revealed high ATV entrapment efficiency (EE%) ranging from 55.62 to 83.91%.,Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344015/),%,55.62 to 83.91,272370,DB01076,Atorvastatin
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],60.47,272796,DB01076,Atorvastatin
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],30.56,272797,DB01076,Atorvastatin
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],98.74,272798,DB01076,Atorvastatin
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],49.21,272799,DB01076,Atorvastatin
,32463566,apparent total clearance,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[l] / [h],330.7,272800,DB01076,Atorvastatin
,32463566,apparent total clearance,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[l] / [h],654.5,272801,DB01076,Atorvastatin
,32463566,apparent volume of distribution,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),l,"2,609",272802,DB01076,Atorvastatin
,32463566,apparent volume of distribution,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),l,"7,159",272803,DB01076,Atorvastatin
,11217766,overall run time,"For this particular analysis, the parallel chromatography system decreased the overall run time from 4.5 to 1.65 min and, therefore, increased the overall throughput by a factor of 2.7 in comparison to a conventional LC/MS/MS analytical method.",A four-column parallel chromatography system for isocratic or gradient LC/MS analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217766/),min,4.5,273579,DB01076,Atorvastatin
,11217766,overall run time,"For this particular analysis, the parallel chromatography system decreased the overall run time from 4.5 to 1.65 min and, therefore, increased the overall throughput by a factor of 2.7 in comparison to a conventional LC/MS/MS analytical method.",A four-column parallel chromatography system for isocratic or gradient LC/MS analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217766/),min,1.65,273580,DB01076,Atorvastatin
